The effect of a phenacyl imidazolium compound (LY177507 or Proglycosyn, Eli Lilly) on the direct (glucose-->glucose-6-phosphate-->glycogen) and indirect (three-carbon compounds-->glucose-6-phosphate-->glycogen) pathways of liver glycogen synthesis was studied in conscious rats. [1-13C]Glucose (99% enriched) was infused intraduodenally into chronically catheterized Proglycosyn-treated (n = 7) and saline-treated (n = 7) rats for 120 min. Net hepatic glycogen synthetic rates were increased twofold in drug-treated rats compared with saline-treated controls. The percentage of liver glycogen synthesized by the direct pathway was calculated by comparing the 13C isotopic enrichment in the C1 and C6 positions of hepatic glycogen and plasma glucose using 13C nuclear magnetic resonance spectroscopy and gas chromatography-mass spectroscopy techniques and was found to be 59 +/- 5% and 39 +/- 2% (P < 0.05) in the saline treated and Proglycosyn-treated groups, respectively. Net flux rates for the direct and indirect pathways were calculated to be 0.24 +/- 0.04 and 0.17 +/- 0.03 mumol/g liver per min, respectively, in the saline-treated group and 0.30 +/- 0.04 (P = NS) and 0.46 +/- 0.06 (P < 0.05) mumol/g liver per min, respectively, in the Proglycosyn-treated group. Thus, Proglycosyn increases net hepatic glycogen synthesis in vivo exclusively through augmentation of the indirect pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF00578216 | DOI Listing |
Orphanet J Rare Dis
January 2025
Department of Pediatrics, Guangdong Provincial People's Hospital, The Second School of Clinical Medicine, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
Background: Hepatic glycogen storage diseases (GSD) are inborn errors of metabolism with abnormal storage or utilization of glycogen, a complex disease with significant genetic heterogeneity and similar clinical manifestations. This study aimed to describe the gastrointestinal symptoms and endoscopic features of hepatic GSD, including types Ia, Ib, III, VI, and IX, to provide evidence for etiology and treatment.
Methods: A national cohort survey questionnaire was distributed to patients diagnosed with GSD type Ia, Ib, III, VI, and IX through genetic testing or their parents in mainland China in May 2022.
World J Hepatol
January 2025
Postgraduate in Hepatology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050-170, Brazil.
Background: Cirrhotic patients face heightened energy demands, leading to rapid glycogen depletion, protein degradation, oxidative stress, and inflammation, which drive disease progression and complications. These disruptions cause cellular damage and parenchymal changes, resulting in vascular alterations, portal hypertension, and liver dysfunction, significantly affecting patient prognosis.
Aim: To analyze the association between Child-Turcotte-Pugh (CTP) scores and different nutritional indicators with survival in a 15-year follow-up cohort.
Glycogen storage disease type III (GSD III) is a rare metabolic disorder characterized by a deficiency of liver and muscle amylo-1,6-glucosidase. This condition presents with severe hepatic symptoms in childhood, mostly hepatomegaly, hypoglycemia in half of patients, while muscular complications may predominate in adulthood. Hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC) are common complications in older patients.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Chinese Osteo-traumatology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, China. Electronic address:
Fatigue is a pathological state that can impair physical and cognitive performance, making the development of effective therapeutic strategies crucial. In this study, an acid polysaccharide (MHa) was isolated from Mentha haplocalyx. Structural analysis showed that MHa (40.
View Article and Find Full Text PDFNutrients
January 2025
Instituto de Bioeletricidade Celular (IBIOCEL): Ciência & Saúde, Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Rua João Pio Duarte Silva, 241, Sala G 301, Florianópolis 88038-000, SC, Brazil.
Diabetes mellitus is a metabolic syndrome that has grown globally to become a significant public health challenge. Hypothesizing that the plasma membrane protein, transient receptor potential ankyrin-1, is a pivotal target in insulin resistance, we investigated the mechanism of action of cinnamaldehyde (CIN), an electrophilic TRPA1 agonist, in skeletal muscle, a primary insulin target. Specifically, we evaluated the effect of CIN on insulin resistance, hepatic glycogen accumulation and muscle and adipose tissue glucose uptake.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!